INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint....
Clinical Trial
GRI Bio Announces Pricing of $4 Million Public Offering
LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for...
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company...
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted...
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral...
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with...
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide...
Expanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose...
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced...
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using...
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose...
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and...
GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib Clinical Trial Evaluating GEN2, a Personalizing, Gene Vector Immunotherapy, in Patients with Advanced Solid Tumors
GEN2’s dose-escalation trial, GVO-1102, will establish the Recommended Phase 2 Dose (RP2D), followed immediately by an expansion phase into 3...
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of...
LabTrace Completes the First Study Using its Blockchain-Based Data Authentication System, Designed to Ensure Data Integrity in Clinical Trials
Parkinson's disease research, sponsored by King's College London, verifies clinical observation data using the Algorand blockchain LONDON, June 27, 2024...